May 24, 2022
NHIA sent a letter to HHS requesting that the agency make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs). HHS’s vaccine program created coverage for home and suite-based infusions of COVID mABs, which is set to expire at the end of the year in which the public health emergency (PHE) is terminated. NHIA points out that access to home infusion for mABs for the treatment and prevention of hospitalization and death due to severe COVID-19 and is critical to maintaining preparedness for potential future variants. With no oral therapies approved for prophylaxis, mABs are the only source of preventive therapy for vulnerable patients who do not respond to vaccines, such as transplant patients, cancer patients, and the immunocompromised.
The National Home Infusion Association (NHIA) has developed a list of medications to serve as a reference when making site of care decisions for patients requiring intravenous (IV) or subcutaneous (SC) infusions. The list of medications reflects current U.S. prescribing practices and was compiled from home infusion providers medication dispensing reports and reviewed by NHIA’s Quality and Standards Committee.
Everyone’s favorite wellness challenge is back! Join the National Home Infusion Foundation and NHIA Staff as we Infuse Wellness across our community this September.
Last week concluded the 2024 National Home Infusion Association Annual Conference (NHIA 2024), which brings together more than 1,600 home and alternate site infusion professionals for four days of networking, education, and exhibits.
